Polymorphic And Pseudopolymorphic Forms Of Pharmaceutical Compound Nxl104

Patent No. EP3269717 (titled "Polymorphic And Pseudopolymorphic Forms Of Pharmaceutical Compound Nxl104") was filed by Pfizer on Oct 8, 2010. The application was issued on Aug 9, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3269717

PFIZER
Application Number
EP17182561A
Filing Date
Oct 8, 2010
Status
Patent Maintained As Amended
May 12, 2023
Publication Date
Aug 9, 2023